Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 1:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Long Covid, Post-treatment Lyme Disease Syndrome, Chronic Fatigue Syndrome, Myalgic Encephalomyelitis
Interventions
Lumbrokinase
Dietary Supplement
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Bacterial Infections
Interventions
KSP-1007, Placebo:0.9% sodium chloride, Meropenem
Drug · Other
Lead sponsor
Sumitovant Biopharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lenexa, Kansas
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of dmLT ID Vaccination in Healthy Adults

NCT02531685
Conditions
Gastroenteritis Escherichia Coli
Interventions
Placebo, Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions
Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine, Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed, GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
10 Years to 17 Years
Enrollment
1,715 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
35
States / cities
Birmingham, Alabama • Huntsville, Alabama • Downey, California + 28 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA Schedule

NCT01641991
Conditions
Bacillus Anthracis (Anthrax)
Interventions
BioThrax®
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
328 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
4
States / cities
Atlanta, Georgia • Cincinnati, Ohio • Houston, Texas + 1 more
Conditions
Lyme Disease
Interventions
T2Lyme Panel testing
Device
Lead sponsor
T2 Biosystems
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Wakefield, Rhode Island • La Crosse, Wisconsin
Conditions
Hidradenitis Suppurativa
Interventions
Ruxolitinib Cream, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
573 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
67
States / cities
Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 57 more
Conditions
Bacterial Vaginosis, Vulvovaginal Candidiasis
Interventions
Phexxi
Drug
Lead sponsor
Queen's Medical Center
Other
Eligibility
18 Years to 54 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Honolulu, Hawaii
Conditions
Cancer, Bacteremia
Interventions
Not listed
Lead sponsor
CAMC Health System
Other
Eligibility
Up to 17 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Charleston, West Virginia
Not listed No phase listed Observational

Immunodeficiency in MS

NCT04447937
Conditions
Multiple Sclerosis, Hypogammaglobulinemia, Immunodeficiency, Infection, Bacterial
Interventions
No Interventions
Other
Lead sponsor
Advanced Neurosciences Institute
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Franklin, Tennessee
Conditions
Pneumococcal Infections
Interventions
PCV21, 20vPCV
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
7 Months to 17 Years
Enrollment
1,268 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
17
States / cities
Paramount, California • Doral, Florida • Hialeah, Florida + 13 more
Completed No phase listed Observational Accepts healthy volunteers

Volatile Organic Compounds in Staphylococcus Aureus Patients

NCT01379053
Conditions
Staphylococcus Aureus, Methicillin-resistant Staphylococcus Aureus, Nosocomial Disease
Interventions
Not listed
Lead sponsor
Landon Pediatric Foundation
Other
Eligibility
1 Year to 85 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Ventura, California
Conditions
Tuberculosis, Pulmonary
Interventions
[18F]-FAPI-74
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Meningococcal Infections, Meningitis
Interventions
Menactra®, Menomune®
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
14 Years to 27 Years
Enrollment
763 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
20
States / cities
Little Rock, Arkansas • Fountain Valley, California • Marietta, Georgia + 15 more
Conditions
Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
Interventions
AFX3772, Prevnar 13, Prevnar 20
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
42 Days to 90 Days
Enrollment
388 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
42
States / cities
Jonesboro, Arkansas • Los Angeles, California • Miami, Florida + 35 more
Conditions
Tinea Corporis
Interventions
Naftin® Cream, 2% (younger pediatric cohort), Naftin® Cream, 2% (older pediatric cohort)
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
2 Years to 11 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
College Station, Texas
Conditions
Chlamydia, Gonorrhea
Interventions
Home screening, Clinic screening
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
14 Years to 45 Years · Female only
U.S. locations
1
States / cities
St Louis, Missouri
Withdrawn No phase listed Observational

Impact of Rapid Detection of MRSA

NCT02027389
Conditions
Staphylococcus Aureus Infections
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Phase 2Phase 3 Interventional Results available

Treating Bacterial Overgrowth in Parkinson's Disease

NCT02470780
Conditions
Parkinson's Disease, Small Intestinal Bacterial Overgrowth
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Eye Infections, Bacterial
Interventions
Betadine, Avenova
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
2
States / cities
Palm Beach Gardens, Florida • San Antonio, Texas
Completed Phase 2 Interventional Accepts healthy volunteers

TOL-463 Phase 2 Study for Vaginitis

NCT02866227
Conditions
Bacterial Vaginosis, Vulvovaginal Candidiasis
Interventions
TOL-463
Drug
Lead sponsor
Toltec Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Birmingham, Alabama • Seattle, Washington
Conditions
Candidiasis, Esophageal, HIV Infections
Interventions
Amphotericin B
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
Bacterial Vaginosis (BV)
Interventions
LUXSOL copper containing cream, Metronidazole gel
Drug
Lead sponsor
CDA Research Group, Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Detroit, Michigan • Philadelphia, Pennsylvania
Conditions
Tuberculosis, Pulmonary, Tuberculosis, Multidrug Resistant, Extensively Drug-Resistant Tuberculosis
Interventions
Delamanid, Optimized Background Regimen (OBR), Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas